An expert forum on how Australia can best fight our greatest killer

Event in collaboration/partnership:



Cancer is already our worst disease, killing almost 50,000 Australians a year, and now causing the greatest health burden of any illness, with around 135,000 Australians expected to be diagnosed with cancer this year. These numbers are expected to rise as the population ages. 

We have seen remarkable public benefits from the sustained efforts to reduce heart disease. How can we apply the same lessons of sustained investment and innovation to cancer? 

Join an internationally acclaimed expert panel as we explore how governments best prioritise resources, investment and targeted innovative treatments, and the societal return from winning the fight against cancer. 



Roy D. Baynes, MD, PhD

Chief Medical Officer, Merck Research Laboratories

Dr Baynes is a world leader in cancer research, pharmaceutical development and clinical practice. 

He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical research, teaching and administration. Dr Baynes has been frequently recognised as one of America’s top physicians and has authored over 150 journal publications .


Professor Ian Olver, AM

Director of the Sansom Institute for Health Research

Professor Ian Olver, AM is Director of the Sansom Institute for Health Research, Professor of Translational Cancer Research and Dean, Research Strategy in the Division of Health Sciences. A renowned oncologist, cancer researcher and bioethicist his research interests are in anticancer drug studies, symptom control, bio-ethics and psycho-oncology, Ian is author of over 250 journal articles and is a regular commentator on cancer issues in Australia and internationally. He was CEO, Cancer Council Australia till 2014, is a past chair of the Medical Oncology Group of Australia. 


Lynne Pezzullo

Managing Partner of Deloitte Canberra

Lynne is lead partner of Health Economics and Social Policy at Deloitte Access Economics. Lynne specialises in health, aged care, disability and social policy reform and advice, cost benefit and cost effectiveness analysis. Lynne is also a reviewer for the Medical Journal of Australia and the British Medical Journal.


Richard Vines

Founder and Director, Rare Cancers Australia

Richard and his wife Kate founded Rare Cancers Australia, a patient advocacy group whose mission is to improve the lives and outcomes for rare cancer patients. Richard is an advocate for cancer patient issues and is co-chair of the Cancer Drugs Alliance Committee, a coalition promoting timely and equitable access to innovative drugs.


When 24 October
Where National Portrait Gallery, King Edward Terrace, Parkes ACT 2600.
Time 12.00pm - 2.00pm, Lunch will be provided free of charge.

For more information or questions about the seminar please email Nicklas Wikblad:


If you like to attend, please complete below form